(Q38049148)

27 August 2017

title

Herpes simplex virus and HIV: genital infection synergy and novel approaches to dual prevention (English)

1 reference

reproductive tract infection

27 August 2017

0 references

prevention of HIV/AIDS

0 references

1 reference

A R Thurman

1

1 reference

27 August 2017

G F Doncel

series ordinal

2

1 reference

27 August 2017

publication date

1 September 2012

1 reference

International Journal of STD & AIDS

27 August 2017

published in

1 reference

27 August 2017

volume

23

1 reference

27 August 2017

issue

9

1 reference

27 August 2017

page(s)

613-619

1 reference

Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Once-daily valacyclovir to reduce the risk of transmission of genital herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Association of herpes simplex virus type 2 infection and syphilis with human immunodeficiency virus infection among men who have sex with men in Peru

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Herpes simplex virus and HIV-1: deciphering viral synergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

NF-kappaB is required for apoptosis prevention during herpes simplex virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Activation of I kappa b kinase by herpes simplex virus type 1. A novel target for anti-herpetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

A human immunodeficiency virus (HIV)-inducing factor from the female genital tract activates HIV-1 gene expression through the kappaB enhancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Induction of innate immune responses in the female genital tract: friend or foe of HIV-1 infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Innate and adaptive immunity against herpes simplex virus type 2 in the genital mucosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Endometrial epithelial cell responses to coinfecting viral and bacterial pathogens in the genital tract can activate the HIV-1 LTR in an NF{kappa}B-and AP-1-dependent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Effect of herpes simplex suppression on incidence of HIV among women in Tanzania

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Recurrence and resistance patterns of herpes simplex virus following cessation of > or = 6 years of chronic suppression with acyclovir. Acyclovir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Acyclovir sensitivity of sequential herpes simplex virus type 2 isolates from the genital mucosa of immunocompetent women

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

High risk of human immunodeficiency virus in men who have sex with men with herpes simplex virus type 2 in the EXPLORE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

A missed point in deciphering the viral synergy between herpes simplex virus and HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Acyclovir: a new use for an old drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Antigen-specific T cells localize to the uterine cervix in women with genital herpes simplex virus type 2 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

A Trial of Topical Acyclovir in Genital Herpes Simplex Virus Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Early, patient-initiated treatment of herpes labialis with topical 10% acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Treatment of herpes simplex labialis with topical acyclovir in polyethylene glycol

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Failure of topical acyclovir in ointment to penetrate human skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Acyclovir in the management of herpes labialis

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Comparison of foscarnet cream, acyclovir cream, and acyclovir ointment in the topical treatment of experimental cutaneous herpes simplex virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Comparison of new topical treatments for herpes labialis: efficacy of penciclovir cream, acyclovir cream, and n-docosanol cream against experimental cutaneous herpes simplex virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Herpes Simplex: Insights on Pathogenesis and Possible Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

After CAPRISA 004: time to re-evaluate the HIV lexicon

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Safety evaluation of 1% tenofovir gel in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Consistent inhibition of HIV-1 replication in CD4+ T cells by acyclovir without detection of human herpesviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Inhibition of HIV-1 infection by zinc group metal compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

The mechanism of the antiherpetic activity of zinc sulphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FIJSA.2012.011356

21 January 2018

Identifiers

DOI

10.1258/IJSA.2012.011356

1 reference

27 August 2017

1 reference